Aspire Biopharma Holdings (ASBP) Preferred Stock Liabilities (2022 - 2024)

Aspire Biopharma Holdings (ASBP) has reported Preferred Stock Liabilities for 3 consecutive years, with $6.7 million the latest figure, recorded in Q4 2024.

• On a quarterly basis, Preferred Stock Liabilities fell 66.49% year-over-year to $6.7 million in Q4 2024; TTM through Dec 2024 was $6.7 million, a 66.49% decrease from a year earlier, with the FY2024 full-year figure at $6.7 million, down 66.49% from the prior year.
• Preferred Stock Liabilities was $6.7 million for Q4 2024 at Aspire Biopharma Holdings, up from $6.5 million in the prior quarter.
• Over five years, Preferred Stock Liabilities peaked at $302.2 million in Q1 2023 and troughed at $6.5 million in Q2 2024.
• A 3-year average of $143.7 million and a median of $20.1 million in 2024 frame the typical range for Preferred Stock Liabilities.
• The widest YoY moves for Preferred Stock Liabilities: up 2.55% in 2023, down 93.37% in 2023.
• Over 3 years, Preferred Stock Liabilities stood at $299.0 million in 2022, then tumbled by 93.34% to $19.9 million in 2023, then slumped by 66.49% to $6.7 million in 2024.
• The last three Preferred Stock Liabilities figures came in at $6.7 million (Q4 2024), $6.5 million (Q2 2024), and $20.1 million (Q1 2024), per Business Quant data.